Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
38 hedge funds and large institutions have $16.8M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
47% more call options, than puts
Call options by funds: $298K | Put options by funds: $203K
5% less funds holding
Funds holding: 40 → 38 (-2)
15% less capital invested
Capital invested by funds: $19.9M → $16.8M (-$3.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.32M |
| 2 |
AIC
AWM Investment Company
New York
|
+$505K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$303K |
| 4 |
Renaissance Technologies
New York
|
+$279K |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.28M |
| 2 |
KAM
Krensavage Asset Management
New York
|
-$241K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$116K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$106K |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
-$59.7K |
JNP Hedge Fund Activity: Q1 2017 in Review
38 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q1 2017, worth a combined $16.8M — down 15% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new JNP positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $3.32M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.28M sold.
- 38 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q1 2017, down from 40 in Q4 2016.
- Funds reported $16.8M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q1 2017, down 15% quarter-over-quarter.
- 7 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q1 2017 and 3 closed out, a net change of +4 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $3.32M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q1 2017 was Stonepine Capital Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q1 2017.